GLP-1 receptor agonists for obesity treatment

Clinical MedicineUpdated Oct 5, 2026Version v1

Evidence

Public papers linked to this topic and used as evidence for gaps, timelines, and knowledge views.

359 papers

Showing 37-48 of total 359 evidence records.

Open a paper to inspect abstract, source links, and topic context.

2026PubMedDirectly related

Dorsomedial striatal GABA dynamics organize palatable reward consumption and are reshaped by GLP-1 receptor agonism.

Copling AN; Dinckol O; Wenger NH; Patel BP; N'Kongolo Lukusa EM; Kutlu MG

2026PubMedDirectly related

Hemodynamic Compromise Due to Semaglutide-Associated Abdominal Distension.

Amdahl MB; Bharadiya V; Obritsch B; Obadi O; Wong MY; Rode MM; Colletti J; Cortes Puentes GA; Chen J; Dahiya G

Jan 1, 2026JACC. Case reports

2026PubMedDirectly related

The effect of submaximal doses of semaglutide on the expression of micro-RNA in patients with obesity: a pilot study.

Jurica J; Miertova Z; Pec MJ; Focko B; Miert A; Tudik P; Nagy N; Sagova I; Pecova M; Bolek T; Galajda P; Sarlinova M; Dvorska D; Brany D; Baranova I; Kapinova A; Dankova Z; Halasova E; Mokan M; Samoš M

Jan 1, 2026Obesity facts

2026PubMedDirectly related

Tirzepatide safety in EudraVigilance: descriptive and disproportionality analysis of preferred terms related to suboptimal treatment outcomes and drug-use-related issues.

Popa Ilie IR; Ghibu S; Butuca A; Dobrea CM; Frum A; Stoicescu L; Homorodean C; Gligor FG; Morgovan C

Jan 1, 2026BMJ open

2026PubMedSupporting evidence

Effects of semaglutide on kidney disease in type 2 diabetes: a randomized placebo-controlled trial.

Tuttle KR; Bjornstad P; Smith C; Pruijm M; McCown PJ; Hodgin JB; Cherney DZI; Belmar N; Chacko MM; Das V; Gunnarsson TP; Idorn T; Schytz PA; Zaratiegui A; Kretzler M

Jan 1, 2026Nature medicine

2026PubMedDirectly related

Diet and nutrition in obesity treated with incretin-based therapies: A scientific statement of the Polish Society of Dietetics.

Kwaśny A; Słoma-Krześlak M; Kostelecki G; Rychter AM; Brzegowy M; Jeziorek M; Kręgielska-Narożna M; Lange E; Boniecka I; Prejbisz A; Dobrowolski P; Czapla M

Jan 1, 2026Advances in clinical and experimental medicine : official organ Wroclaw Medical University

2026PubMedDirectly related

Interactions of Glucagon-Like Peptide-1 Receptor Agonists With GLP-1R-Gs Complex: Insights From Gaussian-Accelerated Molecular Dynamics.

Zhou X; Liu M; Shi Y; Duan X; Gao Y; Han W

Jan 1, 2026Proteins

2026PubMedSupporting evidence

Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial.

Klein KR; Wysham C; Tuttle KR; Davies MJ; Cox D; Chen J; Wu WS; Denning M; Liu R; Ludwig L; Meskimen ER

Jan 1, 2026Lancet (London, England)

2026PubMedDirectly related

Impact of the Four Pillars on Electrolyte Derangements during State-of-the-Art Therapy for Diabetic Kidney Disease.

Yoo MJ; Lee S

Jan 1, 2026Electrolyte & blood pressure : E & BP

2026PubMedSupporting evidence

Melatonin and Diabetic Nephropathy: From Mechanistic Pathways to Translational Opportunities in Clinical Management.

Chapani MS; Ostadmohammadi K; Moulaei-Arani M; Sattari-Arani M; Panahi G; Moeini Taba SM; Sattari-Arani M

Jan 1, 2026Current medicinal chemistry

2026PubMedSupporting evidence

Racial and Ethnic Disparities in Medication Adherence Among Medicare Advantage Enrollees With Diabetes.

Essien UR; Roberts ET; Ruggiero DA; Tang JJ; Raghava S; Ayanian JZ; Tipirneni R

Jan 1, 2026JAMA network open

2026PubMedDirectly related

Outcomes of GLP-1 Receptor Agonist Therapy after Liver Transplantation in Patients with Type 2 Diabetes: A Real-World Cohort Study.

Nguefang GL; Boateng S; Gyabaah S; Konlack JG; Issaka Y; Luna Landa E; Chukwu T; Eze E; Njei B

Jan 1, 2026Journal of gastrointestinal and liver diseases : JGLD